The relevance of this B cell population has been highlighted using blocking anti-CD38 antibodies in chronic lymphocytic leukaemia (CLL) that targets and depletes both B and T regulatory cells. This evidence concerns the gene CD38 and B-cell chronic lymphocytic leukemia.